10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PLEASANTON, Calif. , Nov. 7, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Wolfe Research 2024 Healthcare Conference on Tuesday, November 19, at 1:00 p.m.

10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors PARIS and PLEASANTON, Calif. , Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51  and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer survivors, whose survival mechanisms could hold the key to new therapeutic approaches.

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

10x Genomics, Inc. TXG reported a loss for the third quarter on Tuesday.

These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Cassie Corneau - Senior Director, Head of Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Adam Taich - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Doug Schenkel - Wolfe Research Dan Arias - Stifel Nicolaus Dan Brennan - TD Cowen Mason Carrico - Stephens Puneet Souda - Leerink Partners Rachel Vatnsdal - J.P. Morgan Kyle Mikson - Canaccord Genuity Patrick Donnelly - Citi Michael Ryskin - Bank of America Subbu Nambi - Guggenheim Securities Matt Larew - William Blair Matt Sykes - Goldman Sachs Operator Thank you for standing by.

10x Genomics, Inc. (TXG) Q3 2024 Earnings Call Transcript

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.51 per share a year ago.

10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates

PLEASANTON, Calif. , Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024.

10x Genomics Reports Third Quarter 2024 Financial Results

Inspire Medical Systems Inc

Omnicell

Medical Systems, 10x Genomics and Omnicell have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell

Per a preliminary report from 10x Genomics, the company's revenues will decline for the third quarter. Lower Instruments sales are likely to have been partially offset by consumable sales growth.

Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, 10x Genomics and Omnicell are expected to gain from the GenAI wave.

3 Medical Info Systems Stocks to Gain From Healthcare Digitization

10x Genomics (TXG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

10x Genomics (TXG) Upgraded to Strong Buy: Here's Why

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PLEASANTON, Calif. , Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis.

10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches

10x Genomics has faced significant revenue declines and operational challenges, with Q3 revenue missing expectations and instrument sales dropping 46% year-over-year. Despite the setbacks, consumables and services revenue showed growth, indicating customer retention and continued use of 10x's platforms. The company is undergoing commercial process adjustments and remains confident in its long-term growth prospects, despite current economic pressures and competition.

10x Genomics: Deciphering The Preliminary Q3 Earnings

10x Genomics stock crashed Thursday after the medtech reported preliminary third-quarter sales that widely missed Street expectations.

10x Genomics Crashes After 'Disruptive' Reorg Upsets Third-Quarter Sales

PLEASANTON, Calif. , Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024.

10x Genomics Announces Preliminary Select Third Quarter 2024 Results

PLEASANTON, Calif. , Oct. 1, 2024 /PRNewswire/ -- At the Human Cell Atlas General Meeting held September 29-30 in Milan, Italy, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, shared new details about its upcoming product roadmap and its ongoing strategy to democratize access to single cell analysis.

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

SEATTLE--(BUSINESS WIRE)--Parse announced that the Patent Trial and Appeal Board issued a decision to invalidate all claims in the 10,155,981 patent asserted by 10x Genomics.

In a Key Win for Parse, Patent Trial and Appeal Board Invalidates 10x Genomics Patent Claims

In the September 9 cover article of Cancer Cell, researchers integrated 10x single cell and spatial technologies to identify a mechanism of glioblastoma recurrence in mice and develop a promising potential therapeutic approach. PLEASANTON, Calif.

Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer

PLEASANTON, Calif. , Sept. 3, 2024 /PRNewswire/ --  10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo, a new addition to its fleet of Chromium single cell instruments.

10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research

PLEASANTON, Calif. , Aug. 22, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 10:45 a.m.

10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Revenue for Q2 2024 rose to $153.1 million, up 4% year-over-year but below management's expectations. Operating expense decreased by 10%, resulting in a narrower net loss of $37.9 million.

10x Genomics Cuts 2024 Revenue Outlook as Q2 Sales Miss Estimates

10x Genomics, Inc. (NASDAQ:TXG ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Cassie Corneau - Director-Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel Tejas Savant - Morgan Stanley Madeline Mollman - Wolfe Research Marta Zaremba - JPMorgan Kyle Boucher - TD Cowen Kyle Mikson - Canaccord Genuity Michael Ryskin - Bank of America Matthew Sykes - Goldman Sachs Matt Larew - William Blair Luke Sergott - Barclays Operator Thank you for standing by. My name is Kayla and I will be your conference operator today.

10x Genomics, Inc. (TXG) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.53 per share a year ago.

News for 10X Genomics Stock (TXG)